TD Asset Management Inc Purchases 10,377 Shares of Cencora, Inc. $COR

TD Asset Management Inc grew its position in shares of Cencora, Inc. (NYSE:COR) by 3.9% during the 2nd quarter, Holdings Channel.com reports. The firm owned 279,653 shares of the company’s stock after acquiring an additional 10,377 shares during the period. TD Asset Management Inc’s holdings in Cencora were worth $83,854,000 at the end of the most recent reporting period.

Other institutional investors have also recently modified their holdings of the company. Price T Rowe Associates Inc. MD grew its position in Cencora by 8.9% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 9,647,310 shares of the company’s stock worth $2,682,821,000 after acquiring an additional 787,858 shares during the last quarter. Wellington Management Group LLP grew its position in Cencora by 7.2% during the 1st quarter. Wellington Management Group LLP now owns 5,421,262 shares of the company’s stock worth $1,507,599,000 after acquiring an additional 363,402 shares during the last quarter. Boston Partners grew its position in Cencora by 8.1% during the 1st quarter. Boston Partners now owns 5,411,193 shares of the company’s stock worth $1,505,984,000 after acquiring an additional 404,093 shares during the last quarter. Invesco Ltd. grew its position in Cencora by 42.1% during the 1st quarter. Invesco Ltd. now owns 4,607,964 shares of the company’s stock worth $1,281,429,000 after acquiring an additional 1,364,433 shares during the last quarter. Finally, Goldman Sachs Group Inc. grew its position in Cencora by 9.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,711,281 shares of the company’s stock worth $475,890,000 after acquiring an additional 154,311 shares during the last quarter. 97.52% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities analysts recently issued reports on the company. Weiss Ratings restated a “buy (b)” rating on shares of Cencora in a research report on Wednesday, October 8th. Wall Street Zen lowered Cencora from a “buy” rating to a “hold” rating in a research report on Saturday. Morgan Stanley set a $330.00 price target on Cencora and gave the stock an “equal weight” rating in a research report on Wednesday, July 16th. Evercore ISI set a $340.00 price target on Cencora in a research report on Wednesday, October 8th. Finally, Jefferies Financial Group lifted their price objective on Cencora from $275.00 to $300.00 and gave the stock a “hold” rating in a research report on Monday, June 30th. Nine equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $320.00.

Insider Buying and Selling

In other news, Chairman Steven H. Collis sold 31,350 shares of the firm’s stock in a transaction that occurred on Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total value of $9,087,111.00. Following the completion of the transaction, the chairman owned 305,913 shares in the company, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the firm’s stock in a transaction that occurred on Thursday, September 18th. The shares were sold at an average price of $290.00, for a total value of $1,478,130.00. Following the completion of the transaction, the chief executive officer owned 39,274 shares of the company’s stock, valued at approximately $11,389,460. The trade was a 11.49% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,993 shares of company stock valued at $16,292,923. 10.80% of the stock is currently owned by company insiders.

Cencora Price Performance

Shares of COR stock opened at $317.86 on Wednesday. The firm has a market cap of $61.63 billion, a P/E ratio of 32.70, a P/E/G ratio of 1.48 and a beta of 0.63. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $319.87. The business’s 50 day moving average price is $297.97 and its 200-day moving average price is $292.34. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last released its earnings results on Wednesday, August 6th. The company reported $4.00 EPS for the quarter, beating analysts’ consensus estimates of $3.79 by $0.21. The company had revenue of $80.66 billion during the quarter, compared to analysts’ expectations of $80.34 billion. Cencora had a return on equity of 267.36% and a net margin of 0.60%.The firm’s revenue for the quarter was up 8.7% compared to the same quarter last year. During the same quarter last year, the business posted $3.34 EPS. On average, equities research analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current year.

Cencora Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Stockholders of record on Friday, August 15th were paid a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.7%. The ex-dividend date was Friday, August 15th. Cencora’s dividend payout ratio (DPR) is presently 22.63%.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.